Simplex Trading
LYEL icon

Simplex Trading’s Lyell Immunopharma LYEL Stock Holding History

Simplex Trading’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.9K Buy
693
+656
+1,773% +$15.3K ﹤0.01% 7057
2025
Q4 		$1.14K Sell
37
-125
-77% -$2.8K ﹤0.01% 7998
2025
Q3 		$2K Sell
162
-136
-46% -$1.55K ﹤0.01% 8670
2025
Q2 		$2K Buy
298
+248
+496% +$2.26K ﹤0.01% 8158
2025
Q1 		$0 Buy
50
+19
+61% +$233 ﹤0.01% 9169
2024
Q4 		$0 Buy
+31
New +$615 ﹤0.01% 9160
2024
Q3 		– Sell
-168
Closed -$4.94K – 9110
2024
Q2 		$4K Buy
+168
New +$8K ﹤0.01% 8004
2023
Q4 		– Sell
-28
Closed -$1.01K – 9395
2023
Q3 		$0 Buy
+28
New +$1.33K ﹤0.01% 9330
2023
Q2 		– Sell
-1
Closed -$55 – 9527
2023
Q1 		$0 Buy
+1
New +$53 ﹤0.01% 9678
2022
Q4 		– Sell
-4
Closed -$397 – 9889
2022
Q3 		$0 Sell
4
-165
-98% -$22.3K ﹤0.01% 10483
2022
Q2 		$22K Sell
169
-27
-14% -$2.76K ﹤0.01% 7489
2022
Q1 		$19K Buy
196
+114
+139% +$13.8K ﹤0.01% 8301
2021
Q4 		$12K Buy
+82
New +$18.3K ﹤0.01% 8870

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Simplex Trading's LYEL Position: Q1 2026 in Review

Simplex Trading increased its Lyell Immunopharma (LYEL) stake by 1,773% in Q1 2026, buying an estimated $15.3K and bringing the position to 693 shares worth $13.9K. The position accounts for ﹤0.01% of the portfolio, ranked #7057.

Simplex Trading first reported a position in LYEL in Q4 2021 and has held it in 13 quarters since. The position peaked at $22K in Q2 2022. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Simplex Trading held 693 shares of Lyell Immunopharma worth $13.9K as of Q1 2026.
  • Simplex Trading bought 656 Lyell Immunopharma shares in Q1 2026, an estimated $15.3K.
  • Lyell Immunopharma made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #7057 holding.
  • Simplex Trading first reported a position in Lyell Immunopharma in Q4 2021 and has held it in 13 quarters since.
  • Simplex Trading's Lyell Immunopharma position peaked at $22K in Q2 2022.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.